1Coert A,Geelen J,de Visser J,et al.The pharmacology and metabolism of testosterone undecanoate(TU),a new orally active androgen.Acta Endocrinol (Copenh).1975;79(4):789-800
2Brocks DR,Meikle AW,Boike SC,et al.Pharmacokinefics of testosterone in hypogonadal men after transdermal delivery:influence of dose.J Clin Pharmacol 1996;36(8):732-739
3Wang C,Berman N,Longstreth JA,et al.Pharmacokinetics of transdermal testosterone gel in hypogonadal men:Appficafion of gel at one site versus four sites:A General Clinical Reseach Center Study.J Clin Endocrinol Metab 2000;85(3):964-969
5Wang C.Swerdloff RS,Iranmanesh A,et al.Transdermal testosterone gel improve sexual function,mood,muscle strength,and body composition parameters in hypogonadal men.J Clin Endocrinol Metab 2000;85(8):2839-2853
6Curran MJ,Bihrle W.Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.Urology 1999;53(2):423-424
7Rhoden EL,Morgentaler A.Risks of testosterone-replacement therapy and recommendations for monitoring.N Engl J Med 2004;350(5):482-492
8Agarwal PK.Oefelein MG.Testosterone replacement therapy after primary treatment for prostate cancer.J Urol 2005:173(2):535-536
9Kaufman JM,Graydon RJ.Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.J Urol 2004;172(3):920-922
10Behre HM,Bohmeyer J,Nieschlag E.Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls.Clin Endocrinol 1994;40(3):341-349
